ArticleVeterinary research communications2025
Canine cutaneous melanocytic tumors: main histopathological parameters and the use of a magenta chromogen in immunohistochemical diagnosis.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Histopathological analysis remains the gold standard for diagnosing canine melanocytic tumors, and immunohistochemistry as an auxiliary tool. Given the challenge for immunohistochemical interpretation posed by melanin, a common pigment in the cytoplasm of canine neoplastic melanocytes, particularly when using 3,3'-diaminobenzidine (DAB) chromogen, this study aimed to evaluate the applicability of a magenta-colored chromogen for revealing the immunoreactivity of the well-established antibody Melan-A in 40 canine pigmented cutaneous melanocytic tumors and to analyze the association between several histopathological parameters and the diagnosis. Among the samples, 23 were classified as melanocytomas and 17 as melanomas. Significant associations were found between histopathological diagnosis and parameters such as ulceration, nuclear atypia, pigmentation, modified Clark level, symmetry, tumor margins, predominant cellular morphology, intratumoral necrosis, and lymphoplasmacytic inflammatory infiltrate (p < 0.05). A significant difference in the mean mitotic count was also observed between melanomas and melanocytomas (p < 0.05). All samples were positive for Melan-A. Most melanocytic tumors were heavily pigmented, and from these tumors, the majority exhibited strong cytoplasmic Melan-A immunostaining. The magenta chromogen provided excellent contrast with melanin and was visible in tumors regardless of pigmentation level. The findings of this study underscore the importance of analyzing specific histopathological parameters, which might help to differentiate benign from malignant lesions. Also, our results indicate that the magenta chromogen is both applicable and effective in the analysis of pigmented canine cutaneous melanocytic tumors, mitigating the interference caused by melanin and serving as a viable alternative to DAB in conventional immunohistochemistry. Additionally, these findings open perspectives for future studies applying the magenta chromogen to other melanocytic lineage markers.
Indexed as
Identifiers
41114899What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.